Log in

Relevant bibliographies by topics / Perimenopause / Journal articles

Journal articles on the topic 'Perimenopause'

To see the other types of publications on this topic, follow the link: Perimenopause.

Author: Grafiati

Published: 4 June 2021

Last updated: 3 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Perimenopause.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Anggraeni, Novi. "PENGARUH PENGGUNAAN KONTRASEPSI HORMONAL TERHADAP KELUHAN PERIMENOPAUSE PADA WANITA USIA 45-49 TAHUN DIWILAYAH KERJA UPT PUSKESMAS KLAMPIS KABUPATEN BANGKALAN." JURNAL ILMIAH OBSGIN : Jurnal Ilmiah Ilmu Kebidanan & Kandungan P-ISSN : 1979-3340 e-ISSN : 2685-7987 10, no. 1 (November 27, 2019): 54–62. http://dx.doi.org/10.36089/job.v1i1.75.

Full text

Abstract:

Perimenopause is the transition between pre menopausal and postmenopausal. This transition occur sin women aged 45-55 years as aresul to fade crease in sex hormones, namely estrogen and progesterone. As a result of the hormone efficiency appears to complaints called perimenopause complaints that are affected by the use of hormonal contraceptives. Yield data of women aged 45-49 years who use hormonal contraceptives as many as 60 people and are non-hormonal many as 14 people (40%). The purpose of this study was to analyze the influence of hormonal contraceptive use on the complaint perimenopausal women aged 45-49 years in there gion of UPT Puskesmas Klampis Bangkalan. There search design was across sectional, population all mothers aged 45-49 whouse contraceptives as many as 74 people with simple random sampling technique. The independent variables namely the use of contraceptives and the dependent variable is the complaint of perimenopause. Methods of data collection using the questionnaire translated into a frequency distribution ableand narrative, analyzed by statistical test Chi Square with a significance level(α) =0.05 The study of 62 respondents, nearly all mothers are using hormonal contraception (83.9%) and the majority of complaints perimenopause mother is no complaints (67.7%). Complaints perimenopaus al women after use of hormonal contraceptionis almost entirely no complaints easily tired than when we were younger. Statistics Chi Square tests how edthat there is the influence of hormonal contraceptive use on the complaint of perimenopause=0,000. Women should need openness to many health workers ask about the problems of menopause are expected mothers can live a good life with and without interfering with daily activities.

APA, Harvard, Vancouver, ISO, and other styles

2

Soares, Cláudio de Novaes, and Lee Stuart Cohen. "The perimenopause, depressive disorders, and hormonal variability." Sao Paulo Medical Journal 119, no. 2 (March 2001): 78–83. http://dx.doi.org/10.1590/s1516-31802001000200008.

Full text

Abstract:

CONTEXT: Several investigations have postulated that the perimenopause may represent a period of increased psychiatric vulnerability, particularly for mood disorders. This review characterizes the perimenopause, including biological changes, the influence of psychosocial factors and the most common clinical manifestations. Clinic-based studies and community-based surveys addressing the prevalence of depressive symptoms in perimenopausal women are critically reviewed. We also discuss the potential greater vulnerability to mood disturbance during the perimenopause in response to hormonal variability. A therapeutic algorithm for management of depressive symptoms in middle-aged perimenopausal women is also presented. The role of estrogen in the treatment of perimenopausal depressive symptoms is particularly discussed. In addition, we review the existing data regarding the potential efficacy of estrogen as an antidepressant agent (monotherapy, augmentation strategy or prophylaxis). DESIGN: Narrative review.

APA, Harvard, Vancouver, ISO, and other styles

3

Soares, Cláudio N., and Lee S. Cohen. "Perimenopause and Mood Disturbance: An Update." CNS Spectrums 6, no. 2 (February 2001): 167–74. http://dx.doi.org/10.1017/s1092852900007926.

Full text

Abstract:

AbstractThis review characterizes perimenopause, including biologic changes, the influence of psychosocial factors, and the most common clinical manifestations. Clinic-based studies and community-based surveys addressing the prevalence of depressive symptoms in perimenopausal women are critically reviewed. Also discussed is the potentially greater vulnerability to mood disturbance during perimenopause in response to hormonal variability. A therapeutic algorithm for management of depressive symptoms in middle-aged perimenopausal women is presented. The role of estrogen in the treatment of perimenopausal depressive symptoms is addressed. In addition, the article contains a review of the existing data on the potential efficacy of estrogen as an antidepressant agent (monotherapy, augmentation strategy, or prophylaxis).

APA, Harvard, Vancouver, ISO, and other styles

4

Asih, Ni Wayan Dewi Putriny, Cokorda Bagus Jaya Lesmana, Anak Ayu Sri Wahyuni, Ni Ketut Sri Diniari, and Luh Nyoman Alit Aryani. "Correlation between perimenopausal syndromes and depression in nurses at Sanglah General Hospital." Journal of Clinical and Cultural Psychiatry 1, no. 1 (March 2, 2020): 14–17. http://dx.doi.org/10.36444/vii1.008.

Full text

Abstract:

Background: Perimenopause covers the period immediately before the menopause and the first year after the last menstrual period. In addition to the changes in the menstrual cycle, women in the perimenopause phase often report a number of perimenopausal complaints and depressive disorders. This study aims to determine the prevalence of perimenopausal complaints and depression experienced in nurses at Sanglah General Hospital. Methods: The study uses a cross-sectional analytical. The measurement of perimenopause complaints uses the Menopause Rating Scale (MRS) questionnaire and the depression measurement uses the Beck Depression Inventory-II questionnaire (BDI-II). The data are analyzed descriptively, it uses the Fisher test and linear regression test with significance level p <0.05. Results: Nurses who have perimenopausal complaints are 62.7%. Besides, depression is experienced by 23.8% of nurses who have perimenopausal complaints. The complained somatic symptoms with a mild degree are 50% and moderate degree is 40%. While the urogenital sexual symptoms with a moderate degree are 60%, and mild and severe degrees are 20%. Conclusion: This study shows the relationship between perimenopausal complaints and the depression of the nurses in Sanglah General Hospital. Therefore, it is necessary to hold an early detection of depression prevention by screening perimenopausal complaints.

APA, Harvard, Vancouver, ISO, and other styles

5

Bhakta, Amita, Harold Esseku, Yvonne Esseku, Julie Fisher, and Brian Reed. "The hidden WASH needs of perimenopausal women." Journal of Water, Sanitation and Hygiene for Development 11, no. 6 (October 5, 2021): 1016–25. http://dx.doi.org/10.2166/washdev.2021.101.

Full text

Abstract:

Abstract Meeting the needs of an ageing population, particularly in the global South, is increasingly an issue for WASH service provision. An ageing-related issue for women, warranting specific attention from the WASH sector, is the perimenopause, but this is often not discussed publicly. Drawing on data from the UK and Ghana, this paper provides recommendations for meeting the additional WASH needs of women as they experience the perimenopause (the transition period to menopause). Finding these ‘hidden’ needs involved a UK-based phenomenological review and mixed feminist methods in two low-income urban communities in Accra and Kumasi, Ghana. The hidden WASH needs of perimenopausal women included understanding the perimenopause, menstrual hygiene management, urine incontinence management, bathing, and laundry. Community awareness, engagement and empowerment, and ensuring good perimenopausal health can begin to address these needs. Infrastructural measures for perimenopausal women include a continuous water supply, user-friendly bathing and laundry infrastructure, and gender-sensitive, accessible toilets with discrete sanitary disposal bins. High-absorbency sanitary products are important for managing heavy menstruation. A better understanding of the needs of perimenopausal women and training on how to meet these would benefit the WASH sector in ensuring that perimenopausal women are not left behind in efforts to meet the Sustainable Development Goals.

APA, Harvard, Vancouver, ISO, and other styles

6

Bhakta, Amita, Harold Esseku, Yvonne Esseku, Julie Fisher, and Brian Reed. "The hidden WASH needs of perimenopausal women." Journal of Water, Sanitation and Hygiene for Development 11, no. 6 (October 5, 2021): 1016–25. http://dx.doi.org/10.2166/washdev.2021.101.

Full text

Abstract:

Abstract Meeting the needs of an ageing population, particularly in the global South, is increasingly an issue for WASH service provision. An ageing-related issue for women, warranting specific attention from the WASH sector, is the perimenopause, but this is often not discussed publicly. Drawing on data from the UK and Ghana, this paper provides recommendations for meeting the additional WASH needs of women as they experience the perimenopause (the transition period to menopause). Finding these ‘hidden’ needs involved a UK-based phenomenological review and mixed feminist methods in two low-income urban communities in Accra and Kumasi, Ghana. The hidden WASH needs of perimenopausal women included understanding the perimenopause, menstrual hygiene management, urine incontinence management, bathing, and laundry. Community awareness, engagement and empowerment, and ensuring good perimenopausal health can begin to address these needs. Infrastructural measures for perimenopausal women include a continuous water supply, user-friendly bathing and laundry infrastructure, and gender-sensitive, accessible toilets with discrete sanitary disposal bins. High-absorbency sanitary products are important for managing heavy menstruation. A better understanding of the needs of perimenopausal women and training on how to meet these would benefit the WASH sector in ensuring that perimenopausal women are not left behind in efforts to meet the Sustainable Development Goals.

APA, Harvard, Vancouver, ISO, and other styles

7

Nuraeni, Nuraeni, Imas Kania Rahman, and Budi Handrianto. "Kesadaran Religiusitas Orang Dewasa sebagai Solusi bagi Sindrom Perimenopause Menurut Zakiyah Darajat." NUKHBATUL 'ULUM: Jurnal Bidang Kajian Islam 8, no. 2 (December 12, 2022): 108–24. http://dx.doi.org/10.36701/nukhbah.v8i2.563.

Full text

Abstract:

This research discusses perimenopause, which is the period leading up to menopause. This period is the final stage of the biological process experienced by women, where at this time there are various changes both in terms of physical, and psychological. This research aims to provide a solution to the discomfort felt by perimenopause women who actually need help, both by themselves and their environment, with their religious knowledge. This paper uses qualitative methods with this type of literature and field research. The results showed that the situation in the tumultuous perimenopause period, can only be faced by getting close to Allah ﷻ, therefore a perimenopausal woman must further deepen her religious knowledge. The religious knowledge possessed by a perimenopause woman will automatically help fortify her to deal with the turmoil of perimenopause accompanied by the full support of family and the environment. The authors hope that this study can give color to the study of Islamic counseling guidance for adults with cases of perimenopause, and contribute information about all matters related to the perimenopause period to government and private institutions and the wider community so that the resilience of Muslim households can be maintained in the context of feel Calm, love and affection.

APA, Harvard, Vancouver, ISO, and other styles

8

Kaur, Harshiba, and Neerja Goel. "Comparative evaluation of menstrual patterns and hormonal profiles in normal and abnormal perimenopause." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 8, no. 9 (August 26, 2019): 3556. http://dx.doi.org/10.18203/2320-1770.ijrcog20193775.

Full text

Abstract:

Background: Currently there is only one marker to objectively establish perimenopause ie menstrual irregularities. Due to the wide variation in hormones like LH, FSH, estradiol, they become unreliable in predicting approaching menopause. This study was conducted to study and compare the patterns of LH, FSH and Estradiol in normal and abnormal perimenopause using the Stages of Reproductive Ageing Workshop (STRAW) criteria.Methods: A comparative evaluation was done after enrolling 200 patients out of which 100 women were in normal perimenopause (early-25 and late perimenopause-75, depending upon menstrual characteristics as defined by STRAW criteria) and 100 having AUB. Sociodemographic data, presence of menopausal symptoms were recorded. S. LH, S.FSH and S. estradiol we determined by adapted solid phase direct sandwich ELISA.Results: FSH was in menopausal ranges (>20IU/L) in early and late perimenopause. LH and FSH in women with AUB ranged from pre to post menopausal ranges. There was significant difference in LH and FSH between normal perimenopause and abnormal uterine bleeding. Estradiol levels showed a significant difference between late perimenopause and AUB p=0.015.Conclusions: This study shows that there is a progressive incremental trend in FSH and LH and decremental trend in Estradiol from early to late perimenopause due to decrease in ovarian follicular reserve, although the difference is not significant. Clinical symptoms present in 50% of late perimenopausal women showed that besides menstrual characteristics we can correlate these menopausal symptoms with raised FSH and low Estradiol. These women can be picked up and preventive therapy may be provided.

APA, Harvard, Vancouver, ISO, and other styles

9

Nguyen, Thao Thi Phuong, Hai Thanh Phan, Thuc Minh Thi Vu, Phuc Quang Tran, Hieu Trung Do, Linh Gia Vu, Linh Phuong Doan, et al. "Physical activity and social support are associated with quality of life in middle-aged women." PLOS ONE 17, no. 5 (May 6, 2022): e0268135. http://dx.doi.org/10.1371/journal.pone.0268135.

Full text

Abstract:

Purposes This cross-sectional study assessed the quality of life and related factors of Vietnamese women during perimenopause in terms of vasomotor, psychosocial, physical, and sexual aspects. Materials and methods A cross-sectional study on 400 middle-aged women was conducted in Hung Yen, a delta province in Vietnam. Data about socioeconomic characteristics, daily activity patterns, quality of life in terms of vasomotor, psychosocial, physical, and sexual aspects, and level of social support were collected. Tobit multivariate regression model was used to identify factors related to the quality of life among participants. Results The symptoms of perimenopause appeared to worsen with the increase of age and the existence of such health issues as migraine and diabetes. Meanwhile, exercises, recreational activities, and social support appeared to alleviate the negative impact of perimenopausal symptoms on women. Conclusions It is important to address the care needs of women during perimenopausal age, especially their sexual well-being, and development of specific healthcare services and programs focusing on sport, entertainment, and support for women in perimenopause should be facilitated.

APA, Harvard, Vancouver, ISO, and other styles

10

Li, Rui-xia, Min Ma, Xi-rong Xiao, Yan Xu, Xiu-ying Chen, and Bin Li. "Perimenopausal syndrome and mood disorders in perimenopause." Medicine 95, no. 32 (August 2016): e4466. http://dx.doi.org/10.1097/md.0000000000004466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Santi, Nur, Zelna Yuni Andryani, and A. Tihardimanto. "MANAJEMEN ASUHAN KEBIDANAN PERIMENOPAUSE PADA NY “N” DENGAN MENSTRUASI TIDAK TERATUR DI PUSKESMAS KASSI-KASSI KOTA MAKASSAR TAHUN 2021." Jurnal Midwifery 4, no. 1 (February 26, 2022): 19–29. http://dx.doi.org/10.24252/jmw.v4i1.25732.

Full text

Abstract:

Introduction Perimenopause is a transitional period between premenopause and postmenopause. During the period, natural complaints may occur such as irregular menstruation, hot flushes, and sleeping disorders. Women with irregular menstruation are likely to require midwifery care in order to overcome its various negative effects including anxious feeling, fear, which are normal for perimenopausal women before menopause. The main objective of this research was to investigate perimenopause Midwifery Care Management in Mrs. "N" with Irregular Menstruation at Kassi-Kassi Health Center of Makassar. This research was conducted based on the 7 stages of Varney management approach and SOAP documentation procedure. The findings of this research indicated that Mrs."N" experienced irregular menstruation during her perimenopause. However, there were no obstacles and issues found during the care. The monitoring was carried out 4 times for approximately 2 months in which the major complaint by Mrs N was the irregular menstrual cycles. It was also apparent that she felt hot and had trouble sleeping at night. After she was given care or information related to perimenopause, the patient was no longer complaining and was more receptive to the conditions she experience. Conclusion This research concludes that the 7 stages of Varney manageent approach and SOAP documentation procedure could be used as treatment procedure to overcome the issue related to perimenopause. The management approach and procedure were successfully conducted in which the patient could understand her condition after she was given information and knowledge related to various symptoms of perimenopause.

APA, Harvard, Vancouver, ISO, and other styles

12

Shi, Xiao-Lan, Chen Zhao, Shuai Yang, Xiao-Ying Hu, and Shi-Min Liu. "Moxibustion Reduces Ovarian Granulosa Cell Apoptosis Associated with Perimenopause in a Natural Aging Rat Model." Evidence-Based Complementary and Alternative Medicine 2015 (October 13, 2015): 1–9. http://dx.doi.org/10.1155/2015/742914.

Full text

Abstract:

In recent years, concerns about the adverse effects of hormone replacement therapy have increased interest in alternative therapies for the management of the symptoms of perimenopause. Here, we investigated the effects of moxibustion, a traditional Chinese practice that is involved in heated Artemisia vulgaris (mugwort) stimulation, on hormonal imbalance and ovarian granulosa cell (GC) apoptosis in a rat model of perimenopause. Our results showed that mild warm moxibustion (MWM) modulated the circulating levels of estradiol and follicle-stimulating hormone and their receptors and inhibited apoptosis in the ovaries of perimenopausal rats, similar to the effect of estrogen. Further investigation revealed that the effects of MWM on ovary tissues and cultured GCs were mediated by the modulation of the activity of Forkhead box protein O1 and involved the JAK2/STAT3 pathway. Our results provide information on the factors and pathways modulated by MWM and shed light on the mechanism underlying the beneficial effect of moxibustion on the symptoms of perimenopause.

APA, Harvard, Vancouver, ISO, and other styles

13

McNamara, Megan, Pelin Batur, and Kristi Tough DeSapri. "Perimenopause." Annals of Internal Medicine 162, no. 3 (February 3, 2015): ITC1. http://dx.doi.org/10.7326/aitc201502030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

LOBO, ROGERIO A. "PERIMENOPAUSE." Clinical Obstetrics and Gynecology 41, no. 4 (December 1998): 894. http://dx.doi.org/10.1097/00003081-199812000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Perimenopause." Clinical Obstetrics and Gynecology 41, no. 4 (December 1998): 988–89. http://dx.doi.org/10.1097/00003081-199812000-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Sturdee, David. "Perimenopause." Climacteric 12, no. 3 (January 2009): 276. http://dx.doi.org/10.1080/13697130902936406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Contestabile, Elizabeth, and Christine Derzko. "Perimenopause." Journal of Obstetrics and Gynaecology Canada 24, no. 10 (October 2002): 12–17. http://dx.doi.org/10.1016/s1701-2163(17)31075-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Contestabile, Elizabeth, and Christine Derzko. "Perimenopause." Journal SOGC 23, no. 9 (September 2001): 836–41. http://dx.doi.org/10.1016/s0849-5831(16)30403-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Burkman, Ronald T. "Perimenopause." Obstetrics and Gynecology Clinics of North America 29, no. 3 (September 2002): xi—xii. http://dx.doi.org/10.1016/s0889-8545(02)00018-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rayburn, William F. "Perimenopause." Obstetrics and Gynecology Clinics of North America 38, no. 3 (September 2011): xv—xvi. http://dx.doi.org/10.1016/j.ogc.2011.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Traxler, Marsha. "Perimenopause." Journal of Obstetric, Gynecologic & Neonatal Nursing 22, no. 6 (November 1993): 478. http://dx.doi.org/10.1111/j.1552-6909.1993.tb01830.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

LYNDAKER, CAROLYN Z., and LINDA J. HULTON. "PERIMENOPAUSE." Journal of Christian Nursing 22, no. 2 (2005): 25–28. http://dx.doi.org/10.1097/01.cnj.0000262291.41310.ee.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Pollow, Dennis P., Melissa J. Romero-Aleshire, Jessica N. Sanchez, John P. Konhilas, and Heddwen L. Brooks. "ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 309, no. 12 (December 15, 2015): R1546—R1552. http://dx.doi.org/10.1152/ajpregu.00170.2015.

Full text

Abstract:

Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg−1·min−1) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17β-estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17β-estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.

APA, Harvard, Vancouver, ISO, and other styles

24

Ornello, Raffaele, Eleonora De Matteis, Chiara Di Felice, Valeria Caponnetto, Francesca Pistoia, and Simona Sacco. "Acute and Preventive Management of Migraine during Menstruation and Menopause." Journal of Clinical Medicine 10, no. 11 (May 24, 2021): 2263. http://dx.doi.org/10.3390/jcm10112263.

Full text

Abstract:

Migraine course is influenced by female reproductive milestones, including menstruation and perimenopause; menstrual migraine (MM) represents a distinct clinical entity. Increased susceptibility to migraine during menstruation and in perimenopause is probably due to fluctuations in estrogen levels. The present review provides suggestions for the treatment of MM and perimenopausal migraine. MM is characterized by long, severe, and poorly treatable headaches, for which the use of long-acting triptans and/or combined treatment with triptans and common analgesics is advisable. Short-term prophylaxis with triptans and/or estrogen treatment is another viable option in women with regular menstrual cycles or treated with combined hormonal contraceptives; conventional prevention may also be considered depending on the attack-related disability and the presence of attacks unrelated to menstruation. In women with perimenopausal migraine, hormonal treatments should aim at avoiding estrogen fluctuations. Future research on migraine treatments will benefit from the ascertainment of the interplay between female sex hormones and the mechanisms of migraine pathogenesis, including the calcitonin gene-related peptide pathway.

APA, Harvard, Vancouver, ISO, and other styles

25

Islamova, A. O. "Phytotherapy of menopausal disorders." HEALTH OF WOMAN, no. 9(145) (November 30, 2019): 58–63. http://dx.doi.org/10.15574/hw.2019.145.58.

Full text

Abstract:

A study to examine the efficacy and safety of drug Menomedin in patients with climacteric disorders of mild to moderate severity in late reproductive period was performed. The average menopausal index, according to a Menopause Rating Scale (MRS), was significantly lower after treatment (8.6±0.1) than before treatment (23.2±0.5). In all examined women hormone levels corresponded to perimenopausal values. Side effects and individual intolerance reactions were not observed. Antiatherosclerotic effect was detected during treatment Menomedin. Author of the study conclude that a good level of efficacy and safety Menomedin allows to use it at the earliest manifestations of menopausal disorders in women in the late reproductive period (perimenopause). Key words: climacteric syndrome, perimenopause, Menomedin.

APA, Harvard, Vancouver, ISO, and other styles

26

Reza Selviana Nur, Anieq Mumthi’ah Al-Kautzar, and Andi Dian Diarfah. "MANAJEMEN ASUHAN KEBIDANAN PERIMENOPAUSE PADA NY “S” DENGAN OLIGOMENORE DI PUSKESMAS PATTALLASSANG KAB. TAKALAR." Jurnal Midwifery 4, no. 2 (September 1, 2022): 42–52. http://dx.doi.org/10.24252/jmw.v4i2.29591.

Full text

Abstract:

Introduction Perimenopause refers to the period during which the women’s body makes the natural transition to menopuse, marking the end of the reproductive years. Perimenopause is characterized by several symptoms including irregular menstrual cycles, hot flushes, and sleep disturbances. Moreover, during perimenopasue, women with oligomenorrhea need midwifery care in order to overcome the effects of a prolonged menstrual cycle such as the feeling of anxiety. Therefore, based on the aforementioned proble, the major purpose of this study was to investigate and conduct Perimenopausal Midwifery Care Management on Mrs “S” with the case of oligomenorrhea at Pattallassang Health Center of Takalar Regency. Method The research was conducted according to the 7-stages Varney management approach. Result The findings of this study indicated that there were no obstacles found during the care and treatment given to Mrs “S”. However, by the time the care was given, the patient occasionally complained to be feeling hot. She had also experienced sleeping troubles at night. Subsequently, after the treatment and counseling were give, the patient understood her condition and tried to recover by the assistances of the health workers. Conclusion This study concluded that in general, the condition of the patient was considered to be good. She experienced composmentis consciousness, and her vital signs were within normal limits. Moreover, the results of her physical examination showed no signs of abnormalities. Therefore, it could be suggested that there were no major problems found on the case of Mrs “S” with her oligomenorrhea. Hence, the findings of this study are in accordance with theories related to midwifery care management.

APA, Harvard, Vancouver, ISO, and other styles

27

Del Rio, G., R. Menozzi, G. Zizzo, A. Avogaro, P. Marrama, and A. Velardo. "Increased cardiovascular response to caffeine in perimenopausal women before and during estrogen therapy." European Journal of Endocrinology 135, no. 5 (November 1996): 598–603. http://dx.doi.org/10.1530/eje.0.1350598.

Full text

Abstract:

Del Rio G, Menozzi R, Zizzo G, Avogaro A, Marrama P, Velardo A. Increased cardiovascular response to caffeine in perimenopausal women before and during estrogen therapy. Eur J Endocrinol 1996; 135:598–603. ISSN 0804–4643 Perimenopause and menopause may be associated with an increased risk of cardiovascular disease, so we have investigated the cardiovascular and catecholamine response to caffeine in perimenopausal women compared to young cycling premenopausal subjects. Caffeine (250 mg per os) was administered to nine perimenopausal women and nine premenopausal women. The perimenopausal women repeated the test after 4 months of percutaneous estrogen replacement therapy. Systolic and diastolic blood pressure, pulse rate, plasma norepinephrine, epinephrine, glucose, insulin and free fatty acids were determined at 0, 15, 30, 45, 60, 90 and 120 min after caffeine administration. No differences were found in the basal values of systolic blood pressure, diastolic blood pressure, pulse rate, norepinephrine, epinephrine, insulin, glucose and free fatty acids between perimenopausal women, both before and after therapy, and premenopausal women. Caffeine induced a higher increase of systolic (F = 4.9; p < 0.05) and diastolic blood pressure (F = 4.7; p < 0.05) in perimenopausal women before and during estrogen therapy as compared with premenopausal women. Pulse rate increased significantly only in perimenopausal women before therapy (F = 6.5; p < 0.03). These data show that perimenopause either before or during short-term estrogen therapy is associated with enhanced cardiovascular reactivity to caffeine. This phenomenon is not due to increased adrenergic and metabolic responses. Graziano Del Rio, Department of Internal Medicine via del Pozzo, 71 41100 Modena, Italy

APA, Harvard, Vancouver, ISO, and other styles

28

Bhatta, Nirmala, and Roshani Khatry. "Stress and Coping among Perimenopausal Women." International Journal of Research and Review 9, no. 11 (November 22, 2022): 362–70. http://dx.doi.org/10.52403/ijrr.20221149.

Full text

Abstract:

Introductions: Perimenopause is a transitional stage to menopause. Women may experience greater severity of perimenopausal symptoms associated with an increased level of stress. Experience of perimenopausal symptoms will have a direct effect on how women cope with stress. Aim: To identify stress and coping among perimenopausal women. Methods: A cross-sectional analytical study was carried out at gynecological and female OPD of Patan Hospital, Lalitpur among 379 perimenopausal women by purposive sampling. Participants were interviewed using Modified Perceived Stress Scale to measure subjective stress perceptions and Modified Brief COPE Inventory to measure specific coping behavior. Data were analyzed using Statistical Package for Social Sciences version 16. Frequency, mean, standard deviation, and chi-square were calculated for stress and coping. Spearman’s correlation coefficient was used to examine the relationship between stress and coping. Results: More than half 207 (54.62%) of the perimenopausal women experienced low, 134 (35.35%) experienced moderate, and only 38 (10.03%) experienced high stress level. Among them 334 (88.13%) used problem-focused, 324 (85.49%) used emotion-focused, and 310 (81.80%) used dysfunctional coping in high level. There were significantly weak negative correlation of stress with problem-focused (r = -.132, p = .010) and emotion-focused (r=-.248, p=0.00) coping. Conclusion: More than half of the perimenopausal women experienced low stress. The mostly used coping method was problem-focused coping. Women going through perimenopause should be offered education and support for all aspects of this. Stress reduction interventional programs should be designed at community levels. Keywords: coping, perimenopausal women, stress.

APA, Harvard, Vancouver, ISO, and other styles

29

Pizova, N. V., N. A. Pizov, and A. V. Pizov. "Perimenopausal period and mood disorders." Meditsinskiy sovet = Medical Council, no. 4 (April 20, 2021): 230–39. http://dx.doi.org/10.21518/2079-701x-2021-4-230-239.

Full text

Abstract:

The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.

APA, Harvard, Vancouver, ISO, and other styles

30

Butarelli, Marco, C. Bodmer, D. Wunder, and Martin Birkhäuser. "Hormonal contraception in perimenopausal women." Therapeutische Umschau 58, no. 9 (September 1, 2001): 555–63. http://dx.doi.org/10.1024/0040-5930.58.9.555.

Full text

Abstract:

Die Perimenopause ist ein physiologischer Vorgang, der von klimakterischen Symptomen begleitet sein kann. Diese erfordern unter Umständen eine medizinische Behandlung. In der Perimenopause ist die Fertilität zwar reduziert, eine sichere Kontrazeption muss aber mit jeder Frau besprochen werden. Perimenopausale Frauen sollten über die möglichen therapeutischen Prinzipien informiert sein, und selbst, zusammen mit ihrem Arzt, über die durchzuführende Methode oder den Verzicht auf eine Behandlung entscheiden. Orale kombinierte hormonale Kontrazeptiva stellen bei gesunden Frauen ohne Kontraindikationen eine gute und sichere Option dar. Sie gewähren einen sicheren Schwangerschaftsschutz und gleichzeitig eine Behandlung der klimakterischen Symptome. Als kontrazeptive hormonale Alternative stehen die reinen Gestagenpräparate zur Verfügung (Minipille, Depot-Injektionen, Implantate, hormonbeladene Intrauterin-Pessare). Es ist entscheidend, dass jede Frau über die Vor- und Nachteile der kontrazeptiven Methoden informiert ist, so dass sie sich aktiv am therapeutischen Entscheid beteiligen kann.

APA, Harvard, Vancouver, ISO, and other styles

31

LOBO, ROGERIO A. "The Perimenopause." Clinical Obstetrics and Gynecology 41, no. 4 (December 1998): 895–97. http://dx.doi.org/10.1097/00003081-199812000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Speroff, Leon. "The perimenopause." Obstetrics and Gynecology Clinics of North America 29, no. 3 (September 2002): 397–410. http://dx.doi.org/10.1016/s0889-8545(02)00007-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Su, Yuxin, and Danyang Zhang. "Management of menopausal physiological symptoms." Highlights in Science, Engineering and Technology 14 (September 29, 2022): 163–70. http://dx.doi.org/10.54097/hset.v14i.1606.

Full text

Abstract:

With the development of our society, people are putting more and more emphasis on women’s health. Perimenopause is a period that women must experience. When women are in perimenopause, their hormone levels will change greatly, resulting in obvious physiological changes, such as hot flashes, night sweats and other physical symptoms,such as muscle and joint problems, urinal system, and cardiac problems.In fact, there will be a series of psychological changes, such as depression, anxiety and so on, but most of the symptoms will be covered up by physical symptoms, leading to misdiagnosis and missed diagnosis. When patients have negative emotions, they will continue to have an impact on the development of the disease, and even accelerate the development of the disease, gradually forming a vicious circle.It is very important for perimenopausal women to do a good job in hormone supplementation and mental health care, and it is also the key to help perimenopausal women alleviate the physiological and psychological changes caused by menopause. MHT is the first-line recommended treatment, which can also be supplemented by other treatments, such as physical exercise, yoga, warm acupuncture, etc

APA, Harvard, Vancouver, ISO, and other styles

34

Losinski, Genna, Hilary Hicks, Pilar Thangwaritorn, Ilana Engel, Alexandra Laffer, Amy Berkley, and Amber Watts. "Needs Assessment of Perimenopause Resources and Services." Innovation in Aging 5, Supplement_1 (December 1, 2021): 627–28. http://dx.doi.org/10.1093/geroni/igab046.2391.

Full text

Abstract:

Abstract Studies show that women lack knowledge about perimenopause and feel unprepared to make healthcare decisions during this life transition. Most women want to be involved in their healthcare decisions and need timely, free, and accurate information. We conducted a needs assessment in Douglas County, Kansas by systematically reviewing regional organizations that might offer services and resources related to women’s health in midlife. We compared these resources to a benchmark for menopausal care available online nationwide (Gennev.com). We documented the primary purpose of each organization (e.g., cosmetic, wellness, medical care), services and resources offered (e.g., hormone therapy, counseling, non-pharmacological treatments), methods of outreach (e.g., blogs, classes), target audience, costs, and types of service providers (e.g., physician, counselor). We surveyed 9 regional websites: 5 offered medical care, 3 cosmetic and wellness services, 2 were municipal organizations, 2 offered mental health/social support. Four organizations offered services targeted specifically towards perimenopausal women. The most commonly offered services were hormone replacement therapy (44%), nutritional supplements (33%), and weight loss programs (33%). Very few offered educational resources (1) or menopause assessments (1) and none offered tailored psychosocial support for the perimenopause transition. The services offered were expensive with no free services and very few free resources. Organizations were primarily staffed by medical providers, only 1 organization had Menopause Practitioners certified by the North American Menopause Society. Our results demonstrate a need for comprehensive educational and support services for perimenopausal women to fulfill the need for timely, accessible, and accurate information during this understudied health transition.

APA, Harvard, Vancouver, ISO, and other styles

35

Philipp, Claire S., Ambarina Faiz, Nicole Dowling, Anne Dilley, Lisa A. Michaels, Charletta Ayers, Connie H. Miller, Gloria Bachmann, Bruce Evatt, and Parvin Saidi. "Age and the Prevalence of Bleeding Disorders in Women Presenting with Menorrhagia." Blood 104, no. 11 (November 16, 2004): 3080. http://dx.doi.org/10.1182/blood.v104.11.3080.3080.

Full text

Abstract:

Abstract Menorrhagia occurring during adolescence and perimenopause is presumed to be associated with anovulation, and during perimenopause, with uterine pathology, such as subserosal uterine myoma, as well. The frequency of bleeding disorders in women presenting with menorrhagia at the extremes of menstruating age, ie adolescence and perimenopause, are not known. We conducted a study to evaluate the frequency and types of hemostatic defects found in adolescent and perimenopausal age women diagnosed with menorrhagia. 115 women with a physician diagnosis of menorrhagia, including 25 adolescent women, 25 perimenopausal age women, and 65 women between the ages of 20 and 44, underwent comprehensive hemostatic testing for possible bleeding disorders. There were no significant differences between the three age groups in mean hemoglobin, percentage of women with anemia, duration of menses, mean pictorial blood assessment scores, or race. Overall, 48% of women were found to have hemostatic abnormalities. Hemostatic abnormalities among women with menorrhagia Overall ≤ 19 yrs 20–44 yrs ≥ 45 yrs p-value N=115 N=25 N=65 N=25 *Platelet aggregation, Von Willebrand factor, and/or coagulation factor Platelet Aggregation 44% 44% 48% 32% 0.48 Von Willebrand Factor 7% 4% 8% 8% 0.78 Coagulation Factor 5% 8% 6% 0% 0.34 Any Abnormality* 48% 48% 54% 32% 0.32 Adolescents and perimenopausal age women diagnosed with menorrhagia were as likely as women presenting between age 20 to 44 to have underlying hemostatic defects. Among the adolescents, neither age at presentation nor time from menarche were predictive of having a bleeding disorder. The platelet aggregation defects observed were similar among the three age groups with the exception of ADP induced platelet aggregation defects which were seen significantly more frequently in adolescents compared to older women (p≤ 0.01). Ristocetin and epinephrine induced platelet aggregation defects were the most common aggregation defects in women 20 years and older and ADP induced platelet aggregation defects were the most common among adolescents. There were no significant differences in platelet ATP release abnormalities between the three age groups. Our results demonstrate that a high proportion of adolescents and perimenopausal age women presenting with menorrhagia have bleeding disorders. These results suggest that menorrhagia in the adolescent, even if presenting soon after onset of menarche, and in perimenopausal age women, even if fibroids are present, may warrant hemostatic evaluation. Further age-specific studies evaluating treatment benefits and outcomes in women with menorrhagia diagnosed with bleeding disorders are warranted.

APA, Harvard, Vancouver, ISO, and other styles

36

Konhilas, John P., Jessica N. Sanchez, Jessica A. Regan, Eleni Constantopoulos, Marissa Lopez-Pier, Danielle K. Cannon, Rinku Skaria, et al. "Using 4-vinylcyclohexene diepoxide as a model of menopause for cardiovascular disease." American Journal of Physiology-Heart and Circulatory Physiology 318, no. 6 (June 1, 2020): H1461—H1473. http://dx.doi.org/10.1152/ajpheart.00555.2019.

Full text

Abstract:

Before menopause, women are protected against cardiovascular disease compared with age-matched men; this protection is gradually lost after menopause. We present the first evidence that demonstrates menopausal females are more susceptible to pathological cardiac remodeling while perimenopausal and cycling females are not. The 4-vinylcyclohexene diepoxide model permits appropriate examination of how increased susceptibility to the pathological process of cardiac remodeling accelerates from pre- to perimenopause to menopause.

APA, Harvard, Vancouver, ISO, and other styles

37

Rasgon, Natalie, Stephanie Shelton, and Uriel Halbreich. "Perimenopausal Mental Disorders: Epidemiology and Phenomenology." CNS Spectrums 10, no. 6 (June 2005): 471–78. http://dx.doi.org/10.1017/s1092852900023166.

Full text

Abstract:

AbstractPerimenopause, the interval of irregular menstrual activity which directly precedes menopause, is characterized by widely fluctuating hormone levels amidst a large-scale decline in circulating estrogen. This phase in a woman's life is typically accompanied by physical discomforts including vasomotor symptoms, such as headaches, insomnia, and hot flushes, as well as genital atrophy. Not surprisingly, studies suggest a significant increase in mood lability for women during this time. While some evidence points toward an exacerbation of bipolar mood symptoms and an increase in schizophrenic psychosis during perimenopause, the majority of research conducted on perimenopausal mental disorders has focused on unipolar depression. Studies vary widely in methodology, definitions of menopausal status, and degrees of depression among subjects; however, the majority of findings indicate an increased susceptibility to depression during the perimenopausal transition. This greater susceptibility may be due to neuroendocrine effects of declining estrogen levels, the subjective experience of somatic symptoms resulting from this hormonal decline, and/or the more frequent occurrence of “exit” or “loss” events for women during this stage of life. At this time, more research is needed to address questions of prevalence, risk, and etiology for depression and other major mental disorders as related to the physiological and psychosocial changes associated with perimenopause.

APA, Harvard, Vancouver, ISO, and other styles

38

Patroni, Rini. "PERBEDAAN KADAR ASAM URAT PADA WANITA PERIMENOPAUSE DAN MENOPAUSE." JURNAL MEDIA KESEHATAN 10, no. 2 (November 15, 2018): 159–62. http://dx.doi.org/10.33088/jmk.v10i2.338.

Full text

Abstract:

Increased levels of uric acid will occur in women after menopause due to a decrease in estrogen hormones that play an important role in increasing urinary acid excretion through urine. The occurrence of deposition of uric acid continuously in the body so that the kidneys are not able to remove uric acid properly. This study aims to determine differences in uric acid levels in perimenopausal women and menopause at Sukamerindu Health Center Bengkulu City. This study includes comparative study, with cross sectional study design. The sampling technique was purposive sampling as much as 74 respondents, with 37 respondents perimenopause women and 37 respondents of menopause women. Data analysis used univariate and bivariate analysis using independent t test. The mean rate of uric acid levels in perimenopausal women was 5.02 mg / dL while mean menopausal uric acid level was 7.04 mg / dL and after statistical test using independent t test, p value 0.0001, which means p <0, 05 then there are differences in uric acid levels in perimenopausal women and menopause at puskesmas sukamerindu city of Bengkulu. The average uric acid levels in menopausal women is higher compared with perimenopausal women so it is expected for menopausal women to maintain health and consume lots of mineral water so that uric acid does not accumulate in the body.

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Diagnosis of Perimenopause." Nurse Practitioner 28, no. 5 (May 2003): 57. http://dx.doi.org/10.1097/00006205-200305000-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ibrahimi, Khatera, Emile G. M. Couturier, and Antoinette MaassenVanDenBrink. "Migraine and perimenopause." Maturitas 78, no. 4 (August 2014): 277–80. http://dx.doi.org/10.1016/j.maturitas.2014.05.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Pinter, Bojana. "Contraception in perimenopause." Maturitas 124 (June 2019): 171. http://dx.doi.org/10.1016/j.maturitas.2019.04.162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Alexander, J., D. Thompson, L. Dennerstein, G. Bachman, and G. Bachman. "Mood and perimenopause." Journal of Psychosomatic Research 55, no. 2 (August 2003): 128. http://dx.doi.org/10.1016/s0022-3999(03)00482-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Dennersjein, L. "Mood and perimenopause." Journal of Psychosomatic Research 55, no. 2 (August 2003): 129. http://dx.doi.org/10.1016/s0022-3999(03)00486-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Greendale, Gail A., Carol A. Derby, and Pauline M. Maki. "Perimenopause and Cognition." Obstetrics and Gynecology Clinics of North America 38, no. 3 (September 2011): 519–35. http://dx.doi.org/10.1016/j.ogc.2011.05.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Sherman, Carl. "Perimenopause Complicates Treatment." Clinical Psychiatry News 34, no. 7 (July 2006): 20. http://dx.doi.org/10.1016/s0270-6644(06)71558-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Vliet, Elizabeth Lee. "Menopause and Perimenopause." Primary Care: Clinics in Office Practice 29, no. 1 (March 2002): 43–67. http://dx.doi.org/10.1016/s0095-4543(03)00073-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Santoro, Nanette, and Lubna Pal. "Menopause and Perimenopause." Endocrinology and Metabolism Clinics of North America 44, no. 3 (September 2015): xvii—xviii. http://dx.doi.org/10.1016/j.ecl.2015.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Weiss, Gerson. "Understanding the Perimenopause." Women's Health 3, no. 4 (July 2007): 387–90. http://dx.doi.org/10.2217/17455057.3.4.387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Kailas, NA, S. Sifakis, and E. Koumantakis. "Contraception during perimenopause." European Journal of Contraception & Reproductive Health Care 10, no. 1 (March 2005): 19–25. http://dx.doi.org/10.1080/13625180400020861.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Woods, Nancy Fugate, and Ellen Sullivan Mitchell. "Perimenopause: an update." Nursing Clinics of North America 39, no. 1 (March 2004): 117–29. http://dx.doi.org/10.1016/j.cnur.2003.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!